Buy Hexo broncho syrup 100 mg/5 ml 150 ml
  • Buy Hexo broncho syrup 100 mg/5 ml 150 ml

Hexo Broncho [Guaifenesin]

Tamar Orleans
1654 Items
2019-09-19
Dosage form
Brand & Manufacturer
Package Size
$40.56
Quantity
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Expectorant

Indications

Symptomatic therapy of cough, accompanied by obstructed sputum discharge.

Composition

5 ml of syrup contain:

active ingredient: guaifenesin - 100.0 mg;

excipients: levomenthol - 1.10 mg, glucose solution 3492.0 mg, sucrose - 999.0 mg, ethanol 96% - 0.2595 ml, glycerol - 197.0 mg, sodium citrate - 57.0 mg, sodium saccharinate - 15.0 mg, sodium benzoate - 10.0 mg, citric acid monohydrate - 12.0 mg, caramel dye - 6.75 mg, natural sweetener - 2.50 mg, raspberry flavor - 2.28 mg, carbomer 974P - 0,250 mg, crimson dye [Ponso 4R] - 0,250 mg, purified water - qs to 5 ml.

No customer reviews for the moment.

Write your review

Write your review

Hexo Broncho [Guaifenesin]

Dosage and Administration

For oral use. Adults and children over 12 years old: fill the measuring cup to the 10 ml mark and take 10 ml (200 mg of guaifenesin) 4 times a day. The maximum daily dose is 40 ml (800 mg guaifenesin).

Adverse reactions

Adverse reactions identified during post-registration use of the drug were classified as follows: very frequent (≥1 / 10), frequent (≥1 / 100,

Violations of the gastrointestinal tract. Very rarely: abdominal pain, diarrhea, nausea, vomiting.

Immune system disorders. Very rarely: hypersensitivity reactions (including itching and urticaria), rash.

Nervous system disorders. Very rarely: dizziness, headache, drowsiness.

Contraindications

Hypersensitivity to any of the components of the drug, peptic ulcer and 12 duodenal ulcers in the acute stage, children up to 12 years. Breastfeeding period. Surase / isomaltase deficiency, fructose intolerance, glucose-galactose malabsorption.

Carefully:

Pregnancy, severe violations of the liver or kidneys, diabetes.

Drug interactions

Concurrent use with antitussive drugs, including codeine-containing drugs, is not recommended.

Compatible with bronchodilators, antibacterial agents and other drugs taken in the treatment of bronchopulmonary diseases.

Pregnancy and Lactation

Data on the use of the drug "Gekso Bronkho" in pregnant women is not enough. Therefore, it is not recommended to use the drug during pregnancy, except in cases where the expected benefit to the mother outweighs the potential risk to the fetus. Data on the penetration of guaifenesin into breast milk are not available, so breastfeeding should be stopped for the period of treatment.

Special instructions

You should not take the drug for the treatment of persistent or chronic cough, cough for bronchial asthma and cough, accompanied by excessive secretion of sputum, except in cases where the use of the drug recommended by a doctor.

If, after 3-5 days of taking the drug, the cough persists or there is a fever, cough, rash, prolonged headache, you should consult with your doctor.

Information for patients with diabetes mellitus: the content of carbohydrates in a single dose of the drug corresponds to 0.75 bread unit (XE).

The drug "Gexo Broncho" contains ethanol 96% (0.5 ml / 10 ml syrup). The content of ethanol should be considered for patients suffering from alcoholism, women during pregnancy and breastfeeding, children and persons belonging to high-risk groups, such as patients with liver diseases, epilepsy, brain injury, brain diseases.

The guaifenesin metabolite may cause a color change in the determination of 5-hydroxyindolecetic acid and vanillyl almond acid in urine. Reception of the drug should be stopped 24 hours before urine collection for this analysis.

If the medicinal product has fallen into disrepair or the expiration date has expired, do not pour it into sewage or throw it on the street! Put the medicine in the bag and put it in the trash. These measures will help protect the environment!

Impact on the ability to drive trans. Wed and fur .:

During therapy with Hexo Broncho, care must be taken when driving and working with other technical devices that require increased concentration and psychomotor speed, due to the possibility of dizziness and ethanol content.

Overdosage

Symptoms of an overdose are abdominal discomfort (heartburn, nausea, vomiting), drowsiness.

Treatment is symptomatic and supportive.

  • Brand name: Hexo broncho
  • Active ingredient: Guaifenesin
  • Dosage form: Syrup
  • Manufacturer: Tamar Orleans
  • Country of Origin: France

Studies and clinical trials of Guaifenesin (Click to expand)

  1. Bioavailability of dextromethorphan (as dextrorphan) from sustained release formulations in the presence of guaifenesin in human volunteers
  2. Bioavailability of pseudoephedrine from controlled release formulations in the presence of guaifenesin in human volunteers
  3. A sensitive liquid chromatography–electrospray ionization–mass spectrometry method for the simultaneous determination of pentoxyverine citrate and guaifenesin in human plasma—application to pharmacokinetic and bioequivalence studies
  4. ChemInform Abstract: Exploration of L-Proline-Catalyzed α-Aminoxylation of Aldehyde to (S)-Guaifenesin-Related Drug Molecules.
  5. High-Performance liquid chromatography (HPLC) chiral separations of guaifenesin, methocarbamol, and racemorphan
  6. An Electrochemical Sensor Based on Carbon Nanotube Bimetallic Au-Pt Inorganic-Organic Nanofiber Hybrid Nanocomposite Electrode Applied for Detection of Guaifenesin
  7. Quantitative determinations of codeine phosphate, guaifenesin, pheniramine maleate, phenylpropanolamine hydrochloride, and pyrilamine maleate in an expectorant by high-pressure liquid chromatography
  8. Rapid, stability-indicating, high-pressure liquid chromatographic determination of theophylline, guaifenesin, and benzoic acid in liquid and solid pharmaceutical dosage forms
  9. Simultaneous high-pressure liquid chromatographic determination of acetaminophen, guaifenesin, and dextromethorphan hydrobromide in cough syrup
  10. Simultaneous stability-indicating determination of phenylephrine hydrochloride, phenylpropanolamine hydrochloride, and guaifenesin in dosage forms by reversed-phase paired-ion high-performance liquid chromatography
  11. Simultaneous determination of acetaminophen, guaifenesin, pseudoephedrine, pholcodine, and paraben preservatives in cough mixture by high-performance liquid chromatography
  12. Determination of the structure of a synthetic impurity in guaifenesin: Modification of a high-performance liquid chromatographic method for phenylephrine hydrochloride, phenylpropanolamine hydrochloride, guaifenesin, and sodium benzoate in dosage forms
  13. Bioavailability of dyphylline and dyphylline–guaifenesin tablets in humans
  14. Using dispersive liquid–liquid microextraction and liquid chromatography for determination of guaifenesin enantiomers in human urine
  15. Chromatographic behavior of doxylamine succinate, phenylpropanolamine hydrochloride, chlorpheniramine maleate, dextromethorphan hydrobromide, paracetamol, and guaifenesin in ion pair reverse-phase high performance liquid chromatography
  16. Sustained release of guaifenesin and ipriflavone from biodegradable coatings
  17. Absolute configuration and crystal packing for three chiral drugs prone to spontaneous resolution: Guaifenesin, methocarbamol and mephenesin
  18. Determination of guaifenesin in human plasma by liquid chromatography in the presence of pseudoephedrine
  19. Simultaneous determination of dextrorphan and guaifenesin in human plasma by liquid chromatography with fluorescence detection
  20. Sensitive liquid chromatography–tandem mass spectrometry method for the simultaneous determination of paracetamol and guaifenesin in human plasma
  21. Determination of guaifenesin in human serum by capillary gas chromatography and electron capture detection
  22. Voltammetric assay of Guaifenesin in pharmaceutical formulation
  23. Simultaneous, stability indicating, HPLC-DAD determination of guaifenesin and methyl and propyl-parabens in cough syrup
  24. Simultaneous determination of dextromethorphan, dextrorphan, and guaifenesin in human plasma using semi-automated liquid/liquid extraction and gradient liquid chromatography tandem mass spectrometry

8 other products in the same category:

arrow_upward